Skip to Content
Last Updated: 07/21/14

SPECS Projects

Two funding opportunities for SPECS were made available, and the following projects were selected for the SPECS I and SPECS II phases of the program.

SPECS II Projects

The current SPECS II program was initiated in 2010 and supports research teams studying five different types of cancers: Lung, colon, and prostate cancers; acute leukemia; and non-Hodgkin lymphoma. In this program, the clinical need determines which molecular profile will be evaluated. The molecular profiles include diagnostic profiles that characterize specific cancers; prognostic profiles that indicate the likelihood of patient survival, regardless of treatment; and predictive profiles that indicate an individual patient’s response to a specific therapy.

Through a competitive Funding Opportunity Announcement (FOA) the following projects have been selected for the SPECS II Program:

Related Projects:

Evolving from a SPECS I Project, TARGET: Therapeutically Applicable Research to Generate Effective Treatments applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. Find out more here.

SPECS I Projects

The SPECS I program was initiated in 2004, where it supported six research teams studying six different types of cancers. The projects are listed below.

The signatures evaluated in SPECS I were originally discovered by investigators supported by the NCI Director’s Challenge Initiative. Read more here.